Silo Pharma, Inc. 8-K

What Happened

• Silo Pharma, Inc. (SILO) announced on July 9, 2026 that it entered Purchase Agreements with institutional investors and closed the private placement on July 10, 2026. The deal raised net proceeds of approximately $3.5 million.
• The offering included 124,000 shares of common stock at $6.452 per share, pre‑funded warrants to purchase up to 495,965 shares (at $6.4519 each; exercisable at $0.0001 per share), and Series A‑3 and Series A‑4 warrants each to purchase up to 619,965 shares (warrants exercisable immediately at $6.21 per share).

Key Details

• Closing date: July 10, 2026; net proceeds to company: ~ $3.5 million for working capital and general corporate purposes.
• Warrant terms: Series A‑3 expire 5 years after the resale registration statement is effective; Series A‑4 expire 18 months after effectiveness. Placement agent warrants (46,497 shares) have an $8.065 exercise price.
• Ownership caps: exercise limited so a holder would not own more than 4.99% or 9.99% after exercise (adjustable with notice); pre‑funded warrants capped at 9.99%.
• Registration rights: company agreed to file a resale registration statement within 15 days and use best efforts to have it effective within 30 days (60 days if the SEC issues a full review).

Why It Matters

• The financing provides near‑term cash (about $3.5M) to support operations, reducing immediate liquidity risk.
• If all warrants and pre‑funded warrants are exercised, up to roughly 1.9 million additional shares could be issued (including placement agent warrants), which would dilute existing shareholders’ ownership.
• Registration rights mean the purchasers’ shares and underlying shares will be registered for resale relatively quickly, enabling liquidity for new investors once the registration statement is effective.